Found: Fox Foundation1, the largest non-profit funder of Parkinson's research in the world, to prioritise

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of procuring Produodopa via the NHS on the treatment of Parkinson's disease in Newcastle-Under Lyme constituency.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) published guidance recommending foslevodopa–foscarbidopa (Produodopa) for patients with Parkinson’s disease meeting specified clinical criteria, in November 2023. Produodopa is now available to eligible National Health Service patients in England, including in Newcastle-Under Lyme, in line with the NICE’s recommendations.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will take steps to increase the availability of Produodopa for people with Parkinson’s disease in Newcastle-under-Lyme constituency.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) published guidance recommending foslevodopa–foscarbidopa (Produodopa) for patients with Parkinson’s disease meeting specified clinical criteria, in November 2023. Produodopa is now available to eligible National Health Service patients in England, including in Newcastle-Under Lyme, in line with the NICE’s recommendations.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of medication for Parkinson's disease produced by Teva Pharmaceuticals.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

Teva Pharmaceuticals supply a range of medicines to treat Parkinson’s disease. We are not aware of any issues with Teva Pharmaceuticals’ supply of these medicines. Teva Pharmaceuticals discontinued amantadine 100 milligram capsules in July 2024, however alternative suppliers remain in stock, and are able to meet patient demand.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he has taken to help ensure that people with Parkinson’s in Newcastle-under-Lyme constituency receive (a) an early diagnosis and (b) swift treatment.

Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England’s RightCare toolkit and Getting It Right First Time programme aim to improve care for people with Parkinson’s disease by reducing variation and delivering care more equitably across the country.

The National Institute for Health and Care Excellence’s (NICE) guidance, Parkinson’s disease: Diagnosis and management in primary and secondary care, updated in 2017, sets out best practice for clinicians in the identification and treatment of Parkinson’s, in line with the latest available evidence. The guidance states that if Parkinson's is suspected, people should be referred quickly and untreated to a specialist with expertise in the differential diagnosis of this condition.

There are 27 specialised neurological treatment centres across the National Health Service in England, with the nearest to Newcastle-under-Lyme being in the University Hospitals of North Midlands, which provide access to neurological multidisciplinary teams to ensure that patients with Parkinson’s can receive specialised treatment and support, according to their needs.

We expect integrated care boards (ICBs) and NHS trusts to have due regard to relevant NICE guidelines. It is the responsibility of the ICBs, including the Staffordshire and Stoke-on-Trent ICB which covers Newcastle-under-Lyme, to make available appropriate provision to meet the health and care needs of their local population, in line with these NICE guidelines, including diagnosis and treatment.

Found: Parkinson's UK 174. The Patient Safety Commissioner 175.

Found: Ground-breaking cancer and Parkinson's research team given 5 year funding boost

Found: MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

Found: MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

Found: MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

Found: MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

Found: MRI-guided focused ultrasound subthalamotomy for treating Parkinson's

Found: MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

Found: MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

Found: MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

Found: MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

Found: Service User Representative Isabella Goldie, CEO, Deafblind Scotland James Jopling, Director, Parkinson's